TICKERNERD
Menu
CRLCRLHealthcare · Diagnostics & Research

CRL Stock Forecast: Charles River Laboratories International, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$278
−1.28% on the day

The 16 Wall Street analysts covering Charles River Laboratories International, Inc. hold a median 12-month price target of $300 — +7.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 84 of 100 as at 19 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$13.3B
Ticker Nerd rank
84 / 100
Median analyst target
$300
Analysts covering
16
Revenue$1.0B−2.7% y/y
Operating income$119.9M
Net income−$760K
Free cash flow$148.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.1%
1M
−0.4%
YTD
+39.4%
1Y
+77.1%
From 52W high
−6.9%
From 52W low
+91.0%
$146
$299
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CRL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Charles River Laboratories International, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
84 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
90
Accruals
90
Revisions
80
Value
67
Growth
64
Issuance
61
Quality
57
Volatility
47
Size
12

Momentum (90): The shares have been drifting up relative to others.

Volatility (47): The share price moves around a lot.

Size (12): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CRL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CRL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$150$200$250$300Oct 25Jan 26Apr 26Jul 26CRLHigh $320Median $300Low $145

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says16 analysts
13 Buy2 Hold1 Sell
Low $145Median $300High $320

The green dot is the last close — the median target sits +7.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 8 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
11 Sept 2026Evercore ISI GroupMaintainsOutperform$300 → $320
10 Aug 2026TD CowenMaintainsBuy—
10 Aug 2026TD CowenMaintainsBuy$235 → $300
7 Aug 2026Morgan StanleyMaintainsOverweight—
7 Aug 2026Morgan StanleyMaintainsOverweight$260 → $300
6 Aug 2026Evercore ISI GroupMaintainsOutperform$260 → $300
6 Aug 2026Evercore ISI GroupMaintainsOutperform—
6 Aug 2026JP MorganUpgradeOverweight$180 → $310
6 Aug 2026JP MorganUpgradeOverweight—
6 Aug 2026RBC CapitalMaintainsOutperform$215 → $282
6 Aug 2026RBC CapitalMaintainsOutperform—
20 July 2026CLSADowngradeHold$219
20 July 2026CLSADowngradeHold—
13 July 2026MizuhoMaintainsNeutral$192 → $230
13 July 2026MizuhoMaintainsNeutral—
9 July 2026Morgan StanleyMaintainsOverweight$220 → $260
9 July 2026Morgan StanleyMaintainsOverweight—
17 June 2026Morgan StanleyUpgradeOverweight—
29 May 2026CLSAUpgradeOutperform—
8 May 2026BarclaysMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CRL appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CRL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, Charles River Laboratories International, Inc. returned +77.1% against +16.3% for the S&P 500, dividends included.

CRL vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180200Oct 25Jan 26Apr 26Jul 26CRLS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CRL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+2.1%
Analysts raising
12
Analysts cutting
1
Fundamentals

Charles River Laboratories International, Inc. (CRL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
681.3×

Cheaper than 1% of US stocks

Price / sales
3.3×

Cheaper than 37% of US stocks

Price / book
4.7×

Cheaper than 22% of US stocks

EV / EBITDA
19.0×

Cheaper than 16% of US stocks

Growth & margins
Revenue growth (YoY)
−2.7%

Higher than 23% of US stocks

Earnings growth (YoY)
−2.7%

Higher than 33% of US stocks

Gross margin
36.2%

Higher than 44% of US stocks

Operating margin
15.1%

Higher than 72% of US stocks

Net margin
−6.0%

Higher than 23% of US stocks

Returns & dividend
Return on equity
−7.5%

Higher than 37% of US stocks

Return on assets
4.1%

Higher than 71% of US stocks

Dividend yield
0.4%

Higher than 7% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Charles River Laboratories International, Inc. (CRL) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Charles River Laboratories International, Inc. has a market value of $13.3B and an enterprise value of $16.2B.

  • Revenue in the twelve months to 30 June 2026: $4.0B. The latest quarter shrank 2.7% year on year.

  • Net income over the same four quarters: −$236.3M, a −5.9% net margin.

  • Diluted earnings per share, trailing twelve months: $−4.85.

  • Free cash flow in the twelve months to 30 June 2026: $370.6M, after $211.5M of capital spending.

  • Charles River Laboratories International, Inc. spent $324.1M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 47.7M.

  • Trailing P/E: 681.3×; forward P/E: 21.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.43%, paying out 0% of earnings.

  • Charles River Laboratories International, Inc. employs 18,300 people — $219K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 19 Sept 2026

Data provided by Twelve Data

Peers

CRL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
CRLCharles River Laboratories International, Inc.$13.3B
84
ICLRIcon PLC$12.5B
69
RVTYRevvity, Inc.$16.0B
94
MEDPMedpace Holdings, Inc.$17.5B
97
QGENQiagen NV$9.0B
64
GHGuardant Health, Inc.$23.2B
46
LHLabcorp Holdings, Inc.$26.6B
86

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Charles River Laboratories International, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CRL news & analysis

PGNY vs. CRL: Which Stock Is the Better Value Option?

Zacks Investment Research · 18 Sept 2026neutral

Zacks Investment Research published an analysis comparing Progyny (PGNY) and Charles River Laboratories (CRL), both stocks in the Medical Services sector, to determine which presents the better value opportunity for investors at this time.

Why it matters — A CRL watcher would care because this piece frames Charles River Laboratories as a value candidate being directly weighed against a sector peer in a published analyst comparison.

Charles River Leverages Expertise in Rapid and In Vitro Methods to Reduce Cell Banking Timelines

Business Wire · 17 Sept 2026positive

Charles River Laboratories introduced rapid cell banking programs designed to accelerate release timelines for biopharmaceutical and advanced therapy developers, combining rapid cell bank and release packages with advanced characterization using Next-Generation Sequencing (NGS). The programs aim to help developers reach critical milestones faster and bring treatments to patients sooner.

Why it matters — The offering expands Charles River's cell-banking services, potentially strengthening its position in supporting biopharmaceutical and advanced therapy developers.

Charles River Laboratories International, Inc. (CRL) Presents at 2026 Global Healthcare Conference Transcript

Seeking Alpha · 15 Sept 2026neutral

Charles River Laboratories International, Inc. (CRL) presented at the 2026 Global Healthcare Conference, with a transcript of the presentation published by Seeking Alpha. The item covers the company's remarks made during the conference event.

Why it matters — A CRL watcher would care because the conference presentation and transcript offer insights into the company's position and outlook as communicated to the healthcare investment community.

Charles River Laboratories International, Inc. (CRL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · 14 Sept 2026neutral

Charles River Laboratories International, Inc. presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and a transcript of the presentation was published by Seeking Alpha. The transcript documents the company's remarks at the investor conference.

Why it matters — A CRL watcher would care because the presentation transcript offers insight into the company's strategy and outlook as communicated directly to the investment community at a major healthcare conference.

Charles River Laboratories to Present at Morgan Stanley and Baird Conferences

Business Wire · 11 Sept 2026neutral

Charles River Laboratories announced it will present at upcoming Morgan Stanley and Baird conferences, as reported by Business Wire. The announcement was made from the company's headquarters in Wilmington, Massachusetts.

Why it matters — A CRL watcher would care because conference presentations offer investors and analysts an opportunity to hear directly from company leadership about its business.

FAQ

Frequently asked questions about CRL stock

What is the CRL stock price forecast for 2026-2027?

The 16 Wall Street analysts covering Charles River Laboratories International, Inc. have a median 12-month price target of $300, with estimates ranging from $145 to $320. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CRL stock a buy right now?

Of the 16 analysts covering Charles River Laboratories International, Inc., 13 rate it a Buy, 2 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Charles River Laboratories International, Inc. 84 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CRL?

As at 19 Sept 2026, Charles River Laboratories International, Inc. ranks 84 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (90 of 100).

Will CRL stock go up?

No one can know that. What the data says: the median 12-month target from 16 analysts implies +7.9% from the last close, and Ticker Nerd's factor model ranks Charles River Laboratories International, Inc. 84 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CRL stock forecast for 2030?

No analyst covering Charles River Laboratories International, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CRL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $145 to $320 over the next 12 months.

How has CRL stock performed over the past year?

Charles River Laboratories International, Inc. returned +77.1% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Charles River Laboratories International, Inc. do?

Charles River Laboratories International, Inc. is a global drug development services company that supports pharmaceutical, biotechnology, and medical device organizations across the research and preclinical stages.

What is the latest news on CRL?

The most recent item we track (Zacks Investment Research, 18 Sept 2026): "PGNY vs. CRL: Which Stock Is the Better Value Option?". Zacks Investment Research published an analysis comparing Progyny (PGNY) and Charles River Laboratories (CRL), both stocks in the Medical Services sector, to determine which presents the better value opportunity for investors at this time.

Company

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. is a global drug development services company that supports pharmaceutical, biotechnology, and medical device organizations across the research and preclinical stages. Charles River Laboratories provides research models, discovery services, non-clinical safety assessment, and manufacturing-related testing solutions that help clients evaluate new therapies and products before clinical use. Its business spans three main segments: Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions. The company also offers specialized support for biologics, microbial testing, endotoxin testing, and cell-based research, serving customers in life sciences, academia, and government research. Headquartered in Wilmington, Massachusetts, Charles River Laboratories plays a key role in the outsourced research and development ecosystem by supplying the tools, services, and scientific expertise used to advance drug discovery and product safety worldwide.

CEO Ms. Birgit Girshick · 18,300 employees · United States · https://www.criver.com